Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
349.3 EUR | +0.90% | +3.56% | +1.69% |
Business Summary
Number of employees: 1,148
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody-based Medicines
100.0
%
| 391 | 100.0 % | 1,134 | 100.0 % | +190.23% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
87.8
%
| 359 | 91.9 % | 996 | 87.8 % | +177.12% |
EMEA
5.9
%
| - | - | 67 | 5.9 % | - |
Japan
4.6
%
| 15 | 3.8 % | 52 | 4.6 % | +248.00% |
China
1.7
%
| 4 | 1.0 % | 19 | 1.7 % | +368.86% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 52 | 31/12/07 | |
Karl Gubitz
DFI | Director of Finance/CFO | 54 | 31/05/21 |
Filip Borgions
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/14 |
Karen Massey
COO | Chief Operating Officer | 45 | 12/03/23 |
Peter Ulrichts
CTO | Chief Tech/Sci/R&D Officer | 44 | 31/12/22 |
Luc Truyen
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/03/22 |
Beth Delgiacco
IRC | Investor Relations Contact | - | 31/12/17 |
General Counsel | 54 | 13/02/22 | |
Marc Schorpion
HRO | Human Resources Officer | 66 | 30/11/18 |
Arjen Lemmen
PRN | Corporate Officer/Principal | 39 | 31/12/15 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 25/04/17 | |
Joseph deBethizy
BRD | Director/Board Member | 74 | 12/05/15 |
Pamela Klein
BRD | Director/Board Member | 63 | 27/04/16 |
Chairman | 66 | 14/10/08 | |
Founder | 52 | 31/12/07 | |
James Daly
BRD | Director/Board Member | 63 | 07/05/18 |
Steve Krognes
BRD | Director/Board Member | 56 | 26/02/23 |
Camilla Sylvest
BRD | Director/Board Member | 52 | 07/09/22 |
Ana Cespedes
BRD | Director/Board Member | 51 | 11/12/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 59,431,079 | 59,358,579 ( 99.88 %) | 0 | 99.88 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
arGEN-X BV
arGEN-X BV Pharmaceuticals: OtherHealth Technology Part of argenx SE, arGEN-X BV is a Belgian company that manufactures antibody-based medicines. The private company is based in Zwijnaarde, Belgium. |
Pharmaceuticals: Other
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.69% | 22.15B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B | |
-24.71% | 8.24B |
- Stock Market
- Equities
- ARGX Stock
- Company argenx SE